Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term vedolizumab + upadacitinib dual-targeted therapy in moderate to severe ulcerative colitis
ChiCTR2500103783Phase 4Not yet recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Jun 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab and upadacitinib in autoimmune colitis, sponsored by Shanghai Tenth People's Hospital. Primary endpoints: Clinical remission rate at week 8 and Clinical remission rate at week 52. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
vedolizumabupadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2500103783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103783.